Evaluation of Brilliance ESBL agar, a novel chromogenic medium for detection of extended-spectrum-beta- lactamase-producing Enterobacteriaceae.
The aim of this study was to evaluate the performance of Brilliance ESBL agar (OX; Oxoid, Basingstoke, United Kingdom), a novel chromogenic agar for the selective isolation and the presumptive identification of extended-spectrum-beta-lactamase (ESBL)-producing Enterobacteriaceae. A panel of 200 clinical Gram-negative Enterobacteriaceae and nonfermenting isolates with defined resistance mechanisms was inoculated onto OX and onto ChromID ESBL agar (BM; bioMérieux, Marcy l'Etoile, France) chromogenic medium in the first part of the study to evaluate the growth selectivity and chromogenic features of these two media. Of the 156 Enterobacteriaceae challenge isolates, 8 fully susceptible isolates were inhibited, all 98 ESBL producers were detected, and 50 isolates harboring other resistance mechanisms were recovered on both chromogenic agars. In the second phase, 528 clinical samples (including 344 fecal specimens) were plated onto OX, BM, and MacConkey agar with a ceftazidime disk (MCC) for the screening of ESBL-producing Enterobacteriaceae. Growth on at least one medium was observed with 144 (27%) of the clinical samples screened. A total of 182 isolates, including 109 (60%) of Enterobacteriaceae, were recovered and 70 of these (from 59 specimens) were confirmed as ESBL-producing isolates. The sensitivities of MCC, BM, and OX were 74.6%, 94.9%, and 94.9%, respectively. The specificities of MCC, BM, and OX by specimens reached 94.9%, 95.5%, and 95.7%, respectively, when only colored colonies were considered on the two selective chromogenic media. The high negative predictive value (99.3%) found for OX suggests that this medium may constitute an excellent screening tool for the rapid exclusion of patients not carrying ESBL producers.
Huang
Te-Din
TD
Laboratoire de Microbiologie, Cliniques Universitaires Mont-Godinne (UCL), 1 Avenue G. Therasse, 5530 Yvoir, Belgium. te-din.huang@uclouvain.be
Bogaerts
Pierre
P
Berhin
Catherine
C
Guisset
Amelie
A
Glupczynski
Youri
Y
D000362:Agar; D001431:Bacteriological Techniques / Q000379:methods*; D003470:Culture Media / Q000737:chemistry*; D004755:Enterobacteriaceae / Q000201:enzymology* / Q000302:isolation & purification*; D004756:Enterobacteriaceae Infections / Q000382:microbiology; D006801:Humans; D008403:Mass Screening / Q000379:methods; D011237:Predictive Value of Tests; D012680:Sensitivity and Specificity; D001618:beta-Lactamases / Q000096:biosynthesis*
D003470:Culture Media; D000362:Agar; D001618:beta-Lactamases
J Hosp Infect. 1995 Oct;31(2):89-97
8551026
J Clin Microbiol. 2007 May;45(5):1556-60
17329453
J Antimicrob Chemother. 2003 Oct;52(4):591-7
12972449
Lancet. 1987 Aug 8;2(8554):302-6
2886766
J Clin Microbiol. 2001 Jun;39(6):2206-12
11376058
Clin Microbiol Infect. 2008 Jan;14 Suppl 1:90-103
18154532
J Clin Microbiol. 2008 Nov;46(11):3721-7
18845821
J Clin Microbiol. 2006 Feb;44(2):586-8
16455917
Clin Infect Dis. 1999 Dec;29(6):1411-8
10585788
J Hosp Infect. 1997 Jan;35(1):9-16
9032631
J Clin Microbiol. 2007 Feb;45(2):501-5
17182756
J Clin Microbiol. 2002 Jun;40(6):2153-62
12037080
Infect Control Hosp Epidemiol. 2009 Jan;30(1):103-5
19067603
Curr Opin Microbiol. 2006 Oct;9(5):466-75
16942899
J Med Microbiol. 2008 Mar;57(Pt 3):310-315
18287293
Clin Microbiol Rev. 2005 Oct;18(4):657-86
16223952
Clin Infect Dis. 2007 Oct 1;45(7):846-52
17806048